Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

High-frequency monitoring of clonal dynamics in MPN using saliva and peripheral blood during interferon therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

BSBrian J. SworderNPNicholas R. Pannunzio

Discussion

Loading...

Member takes

Overview

Retrospective and prospective analyses reveal neutrophil-to-lymphocyte ratios as potential biomarkers of interferon therapy responses in MPN.

Key Points

  • To evaluate early clonal dynamics and predictive biomarkers in MPN patients undergoing interferon therapy.
  • Conducted a retrospective analysis of 62 MPN patients on interferon therapy
  • Performed a one-year prospective study with 12 patients involving high-frequency saliva collection and blood draws
  • Quantified JAK2V617F variant allele frequency in various biospecimens, including saliva and plasma
  • 87% of IFNα-treated patients achieved hematologic remission, but only 23% had >50% reduction in JAK2V617F VAF
  • Two patterns of early JAK2V617F VAF changes were identified: a transient rise followed by decline and a steady decline
  • Neutrophil-to-lymphocyte ratios were lower in patients exhibiting an initial rise in VAF, correlating with favorable IFNα responses

Cite This Study

Sworder et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6adhttps://doi.org/10.1182/blood-2025-7268
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Digital PCR-based dynamic monitoring of JAK2V617F burden: A decade-long study unravels its prognostic value in MPN treatment response2025
  2. 2Molecular response and outcomes in patients with myeloproliferative neoplasms treated with interferon in the real-world setting.2026 · 1 citations
  3. 3Allele burden expansion in JAK2 V617F and CALR ‐mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment2026
  4. 4Contribution of molecular characterization to the diagnosis of MPN in patients with low JAK2V617F variant allelic fraction in a real-world cohort2025 · 5 citations
  5. 5Association between JAK2V617F variable allele frequency and risk of thrombotic events in patients with myeloproliferative neoplasms2024 · 8 citations